US FDA News: FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women

FDA approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
Read more: FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women